Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Rolf A. Stahel, Urania Dafni et al.|The Lancet Respiratory Medicine|2017Cited by 184
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast CancerElisabetta Munzone, L. J. Blacher, Enrico Campadelli et al.|JAMA Oncology|2023Cited by 37
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztián Homicskó, Rolf A. Stahel, Panagiota Zygoura et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 14